A BILL 
To direct the Secretary of Health and Human Services, 
in consultation with the United States Trade Representa-
tive and other heads of Federal agencies, to submit to 
Congress a report on the impact of a waiver of certain 
obligations of member nations under the Agreement on 
Trade-Related Aspects of Intellectual Property Rights 
on global COVID–19 vaccine access, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
18:05 Jul 08, 2021
H3694
2 
•HR 3694 IH
SECTION 1. INTERAGENCY PUBLIC HEALTH REPORT ON IM-
1
PACT OF TRIPS WAIVER ON GLOBAL COVID– 
2
19 VACCINE ACCESS. 
3
(a) REPORT AND CONCLUSION.—Not later than 60 
4
days after the date of the enactment of this section, the 
5
Secretary of Health and Human Services, in consultation 
6
with the United States Trade Representative, the Sec-
7
retary of Commerce, the Commissioner of Food and 
8
Drugs, and the Director of the Centers for Disease Con-
9
trol and Prevention, shall submit to Congress, and make 
10
publicly available on a public website of the Department 
11
of Health and Human Services, a report containing the 
12
following: 
13
(1) An assessment of how the elimination or 
14
waiver described in subsection (b) would impact each 
15
of the following during the covered period: 
16
(A) Access to COVID–19 vaccines in the 
17
United States. 
18
(B) Access to COVID–19 vaccines globally. 
19
(C) Global COVID–19 vaccine manufac-
20
turing capacity. 
21
(D) Global supply chains of COVID–19 
22
vaccines and related technologies and the inputs 
23
needed to produce those vaccines and related 
24
technologies. 
25
18:05 Jul 08, 2021
H3694
3 
•HR 3694 IH
(E) Exports and imports by the United 
1
States of COVID–19 vaccines and related tech-
2
nologies and the inputs needed to produce such 
3
vaccines and related technologies. 
4
(F) Biopharmaceutical product manufac-
5
turing in the United States and the inputs 
6
needed to produce biopharmaceutical products. 
7
(G) Investment in biopharmaceutical pro-
8
duction in the United States and in research 
9
and development in biopharmaceutical products 
10
to respond to future infectious disease out-
11
breaks and pandemics. 
12
(2) The Secretary’s conclusion on whether an 
13
elimination or waiver, as described in subsection (b), 
14
during the covered period— 
15
(A) will materially increase global COVID– 
16
19 vaccine access; or 
17
(B) will have a negative impact on any of 
18
the factors described in subparagraphs (A) 
19
through (G) of paragraph (1). 
20
(b) USTR OPPOSITION.—The United States Trade 
21
Representative shall oppose an elimination or waiver of an 
22
obligation imposed on members of the World Trade Orga-
23
nization under the Agreement on Trade-Related Aspects 
24
of Intellectual Property Rights with respect to vaccines in-
25
18:05 Jul 08, 2021
H3694
4 
•HR 3694 IH
tended to prevent or mitigate COVID–19, if the Secretary 
1
concludes under subsection (a)(2) that such elimination or 
2
waiver— 
3
(1) will not materially increase global COVID– 
4
19 vaccine access; or 
5
(2) will have a negative impact on any of the 
6
factors described in subparagraphs (A) through (G) 
7
of subsection (a)(1). 
8
(c) COVERED PERIOD DEFINED.—The term ‘‘covered 
9
period’’ means the period beginning on the date of the en-
10
actment of this section and ending on December 31, 2022. 
11
Æ 
18:05 Jul 08, 2021
H3694
